To read Rare and Ultra-Rare Diseases. Prioritisation and Sustainability – a Report from the Front-Line click here
At Amryt Pharma, we look beyond the ordinary, unearthing scientific potential and delivering medicines that may have the potential to change the lives of people with rare, debilitating conditions.
Through our in-depth knowledge and bold approach we combine the expertise and innovation needed to help patients and their caregivers to access new treatments quickly and responsibly.
At Amryt Pharma, we strive to transform the lives of people with rare, debilitating conditions and of those who care for them.
Read more about EB, an unspeakably painful and incurable genetic condition affecting the skin from birth.
Read more
Learn more about HoFH, a rare, life-limiting condition characterised by extreme levels of cholesterol.
Read more
Learn more about lipodystrophy, a rare, complex and heterogeneous disorder characterised by abnormal distribution of fat in the body
Read more
Amryt Pharma is committed to delivering safe and effective medicines that help healthcare professionals treat their most challenging patient cases; transforming lives where it may not have been possible in the past.
Amryt Pharma focuses exclusively on the development and commercialisation of innovative, breakthrough medicines for the treatment of rare, ultra-rare (orphan) and debilitating diseases with high unmet medical need.
Amryt Pharma’s success is built on the strong partnerships we forge with current and future pharmaceutical partners in all territories. We pride ourselves on being nimble and creative when negotiating deals and we believe it is imperative to ensure all parties achieve a mutual benefit.
This is an exciting time for Amryt Pharma. We are a successful, thriving global company poised to achieve unparalleled results.
Our success is driven and defined by the inspiring people who embody our values and wake up every day with the goal of changing lives of people with rare and orphan diseases.
Amryt acquired Aegerion in September 2019 and inherited responsibilities for pre-existing Aegerion legal settlements and compliance obligations